Pembrolizumab-induced Acute Tubulointerstitial Nephritis Accompanying Fanconi Syndrome and Type 1 Renal Tubular Acidosis

Hayato Fujioka; Kota Kakeshita; Teruhiko Imamura; Yu Arisawa; Shingo Yokoyama; Hidenori Yamazaki; Tsutomu Koike; Takashi Minamisaka; Kenichi Hirabayashi; Koichiro Kinugawa

doi:10.2169/internalmedicine.1918-23

Pembrolizumab-induced Acute Tubulointerstitial Nephritis Accompanying Fanconi Syndrome and Type 1 Renal Tubular Acidosis

Hayato Fujioka, Kota Kakeshita, Teruhiko Imamura^*, Yu Arisawa, Shingo Yokoyama, Hidenori Yamazaki, Tsutomu Koike, Takashi Minamisaka, Kenichi Hirabayashi, Koichiro Kinugawa

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

Pembrolizumab, an immune checkpoint inhibitor, is used to treat a variety of refractory malignancies. However, these agents are sometimes associated with immune-related adverse events. A 71-year-old woman received pembrolizumab-integrated chemotherapy to treat her recurrent mandibular gingival cancer. Five months after stopping pembrolizumab, she developed acute tubulointerstitial nephritis associated with Fanconi syndrome and type 1 renal tubular acidosis, which resolved with steroid therapy. We experienced a case of pembrolizumab-induced Fanconi syndrome and type 1 renal acidosis. We recommend follow-up of the tubular function in addition to the renal function even after discontinuation of pembrolizumab.

Original language	English
Pages (from-to)	533-539
Number of pages	7
Journal	Internal Medicine
Volume	63
Issue number	4
DOIs	https://doi.org/10.2169/internalmedicine.1918-23
State	Published - 2024

Keywords

acute kidney injury
immune checkpoint inhibitor
immune-related adverse events

ASJC Scopus subject areas

Internal Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2169/internalmedicine.1918-23

Cite this

@article{3ad28d52253b4d768d251a8c37962212,

title = "Pembrolizumab-induced Acute Tubulointerstitial Nephritis Accompanying Fanconi Syndrome and Type 1 Renal Tubular Acidosis",

abstract = "Pembrolizumab, an immune checkpoint inhibitor, is used to treat a variety of refractory malignancies. However, these agents are sometimes associated with immune-related adverse events. A 71-year-old woman received pembrolizumab-integrated chemotherapy to treat her recurrent mandibular gingival cancer. Five months after stopping pembrolizumab, she developed acute tubulointerstitial nephritis associated with Fanconi syndrome and type 1 renal tubular acidosis, which resolved with steroid therapy. We experienced a case of pembrolizumab-induced Fanconi syndrome and type 1 renal acidosis. We recommend follow-up of the tubular function in addition to the renal function even after discontinuation of pembrolizumab.",

keywords = "acute kidney injury, immune checkpoint inhibitor, immune-related adverse events",

author = "Hayato Fujioka and Kota Kakeshita and Teruhiko Imamura and Yu Arisawa and Shingo Yokoyama and Hidenori Yamazaki and Tsutomu Koike and Takashi Minamisaka and Kenichi Hirabayashi and Koichiro Kinugawa",

note = "Publisher Copyright: {\textcopyright} 2024 The Japanese Society of Internal Medicine.",

year = "2024",

doi = "10.2169/internalmedicine.1918-23",

language = "英語",

volume = "63",

pages = "533--539",

journal = "Internal Medicine",

issn = "0918-2918",

publisher = "Japanese Society of Internal Medicine",

number = "4",

}

TY - JOUR

T1 - Pembrolizumab-induced Acute Tubulointerstitial Nephritis Accompanying Fanconi Syndrome and Type 1 Renal Tubular Acidosis

AU - Fujioka, Hayato

AU - Kakeshita, Kota

AU - Imamura, Teruhiko

AU - Arisawa, Yu

AU - Yokoyama, Shingo

AU - Yamazaki, Hidenori

AU - Koike, Tsutomu

AU - Minamisaka, Takashi

AU - Hirabayashi, Kenichi

AU - Kinugawa, Koichiro

PY - 2024

Y1 - 2024

N2 - Pembrolizumab, an immune checkpoint inhibitor, is used to treat a variety of refractory malignancies. However, these agents are sometimes associated with immune-related adverse events. A 71-year-old woman received pembrolizumab-integrated chemotherapy to treat her recurrent mandibular gingival cancer. Five months after stopping pembrolizumab, she developed acute tubulointerstitial nephritis associated with Fanconi syndrome and type 1 renal tubular acidosis, which resolved with steroid therapy. We experienced a case of pembrolizumab-induced Fanconi syndrome and type 1 renal acidosis. We recommend follow-up of the tubular function in addition to the renal function even after discontinuation of pembrolizumab.

AB - Pembrolizumab, an immune checkpoint inhibitor, is used to treat a variety of refractory malignancies. However, these agents are sometimes associated with immune-related adverse events. A 71-year-old woman received pembrolizumab-integrated chemotherapy to treat her recurrent mandibular gingival cancer. Five months after stopping pembrolizumab, she developed acute tubulointerstitial nephritis associated with Fanconi syndrome and type 1 renal tubular acidosis, which resolved with steroid therapy. We experienced a case of pembrolizumab-induced Fanconi syndrome and type 1 renal acidosis. We recommend follow-up of the tubular function in addition to the renal function even after discontinuation of pembrolizumab.

KW - acute kidney injury

KW - immune checkpoint inhibitor

KW - immune-related adverse events

UR - http://www.scopus.com/inward/record.url?scp=85185216626&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.1918-23

DO - 10.2169/internalmedicine.1918-23

M3 - 学術論文

C2 - 37380456

AN - SCOPUS:85185216626

SN - 0918-2918

VL - 63

SP - 533

EP - 539

JO - Internal Medicine

JF - Internal Medicine

IS - 4

ER -

Pembrolizumab-induced Acute Tubulointerstitial Nephritis Accompanying Fanconi Syndrome and Type 1 Renal Tubular Acidosis

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Fingerprint

Cite this